Prognostic effect of basal-like breast cancers is time dependent: Evidence from tissue microarray studies on a lymph node-negative cohort

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4168-4174

  Mulligan, Anna Marie ^a   Pinnaduwage, Dushanthi ^a   Bull, Shelley B ^a   O'Malley, Frances P ^a   Andrulis, Irene L ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; BREAST TUMOR; COHORT ANALYSIS; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TIME;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 48249142427     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4543     Document Type: Article

References (30)

1. Andrulis IL BS, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-9.
2. Bull SB, Ozcelik H, Pinnaduwage D, et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 2004;22:86-96.
3. Ozcelik H, Pinnaduwage D, Bull SB. TP53 mutation type and ERBB2 amplification affects survival in node-negative breast cancer. Breast Cancer Res Treat 2007;105:255-65.
4. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000;31:406-14
5. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207:251-9
6. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001;94:1-5.
7. Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 2003;34: 362-8.
8. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
9. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158:1245-51.
10. Perou CM, SorlieT, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
11. SorlieT, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
12. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
13. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.
14. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
15. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11: 155-68.
16. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002; 161:1557-65.
17. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
18. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-54.
19. Done S, Arneson NC, Ozcelik H, et al. p53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancer. Breast Cancer Res Treat 2001;65:111-8.
20. O'Malley FP, Parkes R, Latta E, et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Path 2001;115:504-11.
21. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, Inc.; 1981.
22. Tzankov A, Went P Zimpfer A, Dirnhofer S. Tissue microarray technology: principles, pitfalls and perspectives-lessons learned from hematological malignancies. Exp Gerontol 2005;40:737-44.
23. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonalantibodies. JPath1993;169:27-34.
24. Hashimoto T, Tokuchi Y Hayashi M, et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 1999;59:5572-7.
25. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993;90:4961-5.
26. Sommer SS, Cunningham J, McGovern RM. et al. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. J Natl Cancer Inst 1992;84:246-52.
27. Abd El-Rehim DM, Ball G, Pinder SE, et al. Highthroughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses Int J Cancer 2005;116:340-50
28. Sotiriou C, Neo SY McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci U S A 2003;100:10393-8
29. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
30. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4.